Paladin Advisory Group LLC Has $187,000 Stock Position in Pfizer Inc. (NYSE:PFE)

Paladin Advisory Group LLC reduced its position in shares of Pfizer Inc. (NYSE:PFE) by 43.0% during the fourth quarter, according to the company in its most recent 13F filing with the SEC. The firm owned 6,496 shares of the biopharmaceutical company’s stock after selling 4,898 shares during the quarter. Paladin Advisory Group LLC’s holdings in Pfizer were worth $187,000 at the end of the most recent quarter.

A number of other institutional investors have also added to or reduced their stakes in the company. Moneta Group Investment Advisors LLC raised its stake in Pfizer by 89,592.7% during the 4th quarter. Moneta Group Investment Advisors LLC now owns 161,143,638 shares of the biopharmaceutical company’s stock worth $8,257,000,000 after buying an additional 160,963,976 shares during the period. Charles Schwab Investment Management Inc. raised its stake in Pfizer by 10.9% during the 3rd quarter. Charles Schwab Investment Management Inc. now owns 95,772,746 shares of the biopharmaceutical company’s stock worth $3,161,261,000 after buying an additional 9,393,992 shares during the period. Morgan Stanley raised its stake in Pfizer by 0.4% during the 3rd quarter. Morgan Stanley now owns 84,927,802 shares of the biopharmaceutical company’s stock worth $2,817,055,000 after buying an additional 348,628 shares during the period. Norges Bank acquired a new position in Pfizer during the 4th quarter worth approximately $3,150,472,000. Finally, Massachusetts Financial Services Co. MA raised its stake in Pfizer by 9.4% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 60,207,521 shares of the biopharmaceutical company’s stock worth $1,997,083,000 after buying an additional 5,185,453 shares during the period. 68.36% of the stock is owned by institutional investors and hedge funds.

Analyst Upgrades and Downgrades

PFE has been the subject of a number of recent research reports. TD Cowen lowered Pfizer from an “outperform” rating to a “market perform” rating and set a $32.00 price objective for the company. in a report on Thursday, January 4th. Guggenheim initiated coverage on Pfizer in a report on Friday, February 23rd. They set a “buy” rating and a $36.00 price objective for the company. Cantor Fitzgerald reissued an “overweight” rating and set a $45.00 price objective on shares of Pfizer in a report on Monday. Finally, Argus lowered Pfizer from a “buy” rating to a “hold” rating in a report on Friday, March 22nd. Twelve investment analysts have rated the stock with a hold rating and six have issued a buy rating to the stock. According to MarketBeat, the stock has an average rating of “Hold” and a consensus target price of $36.88.

Pfizer Stock Performance

NYSE PFE traded up $0.60 on Friday, hitting $25.99. 38,347,117 shares of the stock traded hands, compared to its average volume of 42,429,016. The business’s fifty day moving average is $27.14 and its two-hundred day moving average is $28.74. Pfizer Inc. has a 12 month low of $25.23 and a 12 month high of $40.37. The firm has a market capitalization of $147.17 billion, a price-to-earnings ratio of 72.22, a PEG ratio of 1.15 and a beta of 0.61. The company has a debt-to-equity ratio of 0.69, a quick ratio of 0.69 and a current ratio of 0.91.

Pfizer (NYSE:PFE) last announced its quarterly earnings data on Tuesday, January 30th. The biopharmaceutical company reported $0.10 earnings per share for the quarter, beating the consensus estimate of ($0.19) by $0.29. Pfizer had a return on equity of 10.88% and a net margin of 3.62%. The business had revenue of $14.25 billion during the quarter, compared to analyst estimates of $14.37 billion. During the same period in the prior year, the company earned $1.14 earnings per share. Pfizer’s revenue was down 41.3% compared to the same quarter last year. As a group, equities analysts anticipate that Pfizer Inc. will post 2.24 EPS for the current fiscal year.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.